Clinical Trial Update: Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) [Phase 2]

View source ↗

Summary

Phase 2 trial of topical ruxolitinib for cutaneous chronic graft-versus-host disease has terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Graft Versus Host Disease, JNS Kinase | Phase 2 | Status: TERMINATED | Results posted: 2022-07-12